Relative to the control group, mifepristone-treated pancreatic tumors showed a decrease in cell-surface PD-L1 (Fig. 6o) as well as an increase in cell-surface MHC-I (H-2Kb; Fig. 6p) and B2M (Fig. 6q), either with or without co-treatment with dual ICB. This evidence concerns the gene B2M and pancreatic neoplasm.